胃泌素抑制肽(GIP)多克隆抗体
Polyclonal Antibody to Gastric Inhibitory Polypeptide (GIP)
Incretin hormone; Glucose Dependent Insulinotropic Peptide
- 编号PAA882Hu01
- 物种Homo sapiens (Human，人)相同的名称，不同的物种。
- 来源多抗制备
- 宿主兔
- 效价-
- Ig类型IgG
- 纯化方式抗原特异性亲和纯化
- 标记物无标记物
- 免疫原RPA882Hu01-胃泌素抑制肽(GIP)重组蛋白
- 缓冲液成份0.01M 磷酸盐缓冲液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性状液体
- 浓度0.5mg/mL
- 且适物种-
- 应用WB; IHC; ICC; IP.
如果抗体需用于流式细胞术，请参见流式抗体。 - 下载英文说明书 中文说明书
- 规格20µl100µl200µl1ml10ml
- 价格¥ 569¥ 1327¥ 1896¥ 4740¥ 18960
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
产品包装(模拟)
产品包装(模拟)
IHC图
Figure. Western Blot; Sample: Recombinant GIP, Human.
通过ISO 9001、ISO 13485质量体系认证
特异性
该抗体是针对GIP的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别GIP。
用法
Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
储存
经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
赠品
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPA882Hu01 | 胃泌素抑制肽(GIP)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| CPA882Hu11 | 胃泌素抑制肽(GIP)牛血清白蛋白偶联物 | Immunogen; SDS-PAGE; WB. |
| CPA882Hu21 | 胃泌素抑制肽(GIP)卵白蛋白偶联物 | Immunogen; SDS-PAGE; WB. |
| PAA882Hu08 | 胃泌素抑制肽(GIP)多克隆抗体 | WB; IHC; ICC; IP. |
| PAA882Hu01 | 胃泌素抑制肽(GIP)多克隆抗体 | WB; IHC; ICC; IP. |
| MAA882Hu21 | 胃泌素抑制肽(GIP)单克隆抗体 | WB; IHC |
| MAA882Hu22 | 胃泌素抑制肽(GIP)单克隆抗体 | WB; IHC |
| MAA882Hu23 | 胃泌素抑制肽(GIP)单克隆抗体 | WB; IHC; ICC; IP. |
| CEA882Hu | 胃泌素抑制肽(GIP)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA882Hu | 胃泌素抑制肽(GIP)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
| KSA882Hu11 | 胃泌素抑制肽(GIP)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". |
参考文献
| 杂志 | 参考文献 |
| Scientific Reports | The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlyingsignaling mechanisms in a rat model of diabetes mellitus.[pubmed:27721485] |
| Obesity surgery | The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats.[pubmed:28840471] |
| Obesity Surgery | Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague …[Pubmed:29098544] |
| BioMed Research International | Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity[] |
| Diabetes Research and Clinical Practice | Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients[Pubmed: 31734225] |
| OBESITY SURGERY | The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats[Pubmed: 31701411] |
| FUTURE SCIENCE | Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes[Pubmed:35251693] |